Abstract: The present invention relates to in vivo stable 197(m)Hg compounds according to formula (E) for use in nuclear medical diagnostics and endoradionuclide therapy (theranostics), particularly the treatment of cancer, a method for the production of the 197(m)Hg compounds comprising the step of radiolabeling of organic precursor compounds with NCA 197(m)Hg by electrophilic substitution; and the use of the 197(m)Hg compounds for nuclear medical diagnostics and endoradionuclide therapy (theranostics), particularly the treatment of cancer.

Abstract: The present invention describes novel chelators (multidentate ligands) and precompounds for complexation of radiometals and non-radioactive counterparts, for use in radiopharmacy. The invention includes a process and a kit involving such chelators. Active moieties directing to a pharmaceutical target (such as peptides or proteins) can be attached to the chelator very easily via the so called “click-chemistry” forming a triazole-ring moiety. The aromatic triazole-nitrogen itself acts as a new and “soft” nucleophilic site enabling for complexation of various radiometals or non-radioactive counterparts. The chelators are capable of fast complexation at low temperature.

Abstract: The present invention relates to in vivo stable 197(m)Hg compounds according to formula (I) for use in nuclear medical diagnostics and endoradionuclide therapy (theranostics), particularly the treatment of cancer, a method for the production of the 197(m)Hg compounds comprising the step of radiolabeling of organic precursor compounds with NCA 197(m)Hg by electrophilic substitution; and the use of the 197(m)Hg compounds for nuclear medical diagnostics and endoradionuclide therapy (theranostics), particularly the treatment of cancer.

Abstract: Provided are radiolytically and metabolically stable metal complexes based on tetrathiol ligands useful for nuclear medical diagnostics and in endoradionuclide therapy. Methods for their preparation are also provided. The complexes can have a central ligand, Y, that can be 99mTcO, 186ReO, 188ReO, 99mTcN, 186ReN or 188ReN.

Abstract: The aim of the invention is to provide radiolytically and metabolically stable metal complexes suitable for conjugation with biomolecules and, therefore, useful for nuclear medical diagnostics and in endoradionuclide therapy and to provide a method for their production.